What happens to nanoparticles when they enter the bloodstream?

Researchers have been exploring the potential of nanoparticles in drug delivery, citing several key advantages. By utilizing these tiny particles, scientists can enable targeted delivery of medications directly to specific areas of the body, thereby reducing the amount of medication required and minimizing side effects. Additionally, nanoparticles can protect active ingredients from premature degradation, extending their duration of action and enhancing their overall efficacy.

However, a significant challenge arises when nanoparticles come into contact with blood. The surface of these particles rapidly adsorbs proteins from the surrounding blood, forming a protein corona. This dynamic layer of proteins profoundly influences the behavior of the nanoparticles, affecting their interaction with cells, distribution within the body, and recognition by the immune system. As a result, the protein corona can either facilitate or hinder the therapeutic effects of the nanoparticles, depending on its composition and structure.

Understanding the protein corona's impact on nanoparticles is crucial for the development of effective and safe drug delivery systems. Further research is needed to elucidate the complex relationships between nanoparticles, proteins, and biological systems, ultimately paving the way for the creation of optimized nanoparticles that can deliver medications with precision and minimal side effects.